Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Tuberculosis Provide written, informed consent prior to all trial-related procedures including HIV testing Male or female, aged between 18 and 65 years, inclusive Body weight (in light clothing and with no shoes) between 40 and 90 kg, inclusive Newly diagnosed, previously untreated, rifampicin-susceptible pulmonary TB A chest X-ray picture which in the opinion of the Investigator is consistent with TB Sputum positive on microscopy for acid-fast bacilli on at least one sputum sample (at least 1+ on the scale) Ability to produce an adequate volume of sputum as estimated from an overnight sputum collection sample (estimated 10 ml or more) Be of non-childbearing potential or using effective methods of birth control throughout participation in the study until Visit 19 (day 28). Non-childbearing potential: 1. Female participant/sexual partner bilateral oophorectomy, bilateral tubal ligation and/or hysterectomy or hasbeen postmenopausal with a history of no menses for at least 12 consecutive months; or 2. Male participant/sexual partner vasectomised or has had a bilateral orchidectomy minimally three month prior to screening; Effective birth control methods: 1. Participant  Evidence of clinically significant conditions or findings, other than the indication being studied, particularly epilepsy, that might compromise safety or the interpretation of trial endpoints, per discretion of the Investigator Poor general condition where any delay in treatment cannot be tolerated per discretion of the Investigator Clinically significant evidence of extrathoracic TB (miliary TB, abdominal TB, urogenital TB, osteoarthritic TB, TB meningitis), as judged by the Investigator Significant history of cardiovascular disease such as heart failure, a personal or family history of congenital QT prolongation, Torsade de Pointes, or QTcF interval > 500 ms (confirmed by repeat electrocardiogram) History of allergy to any of the trial IP/s or related substances i.e. β-lactams and penicillin, as confirmed by the clinical judgement of the Investigator Alcohol or drug abuse, that in the opinion of the Investigator, is sufficient to compromise the safety or cooperation of the participant HIV positive ONLY IF CD4 < 350cells/mm3 On ART Having participated in other clinical studies with investigational agents within 8 weeks prior to trial start